Inhibition of Melanogenesis by the Antidiabetic Metformin - Archive ouverte HAL Access content directly
Journal Articles Journal of Investigative Dermatology Year : 2014

Inhibition of Melanogenesis by the Antidiabetic Metformin

(1) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (1)


Several reports have demonstrated the inhibitory effect of metformin, a widely used drug in the treatment of type 2 diabetes, on the proliferation of many cancers including melanoma. Recently, it has been shown that metformin is able to modulate the cAMP level in the liver. As cAMP has a crucial role in melanin synthesis and skin pigmentation, we investigated the effect of metformin on melanogenesis both in vitro and in vivo. We showed that metformin led to reduced melanin content in melanoma cells and in normal human melanocytes by decreasing cAMP accumulation and cAMP-responsive element-binding protein phosphorylation. This inhibitory effect is correlated with decreased expression of master genes of melanogenesis, microphthalmia-associated transcription factor, tyrosinase, dopachrome tautomerase, and tyrosinase-related protein 1. Furthermore, we demonstrated that the antimelanogenic effect of metformin is independent of the AMPK pathway. Interestingly, topical application of metformin induced tail whitening in mice. Finally, we confirmed the antimelanogenic effect of metformin on reconstituted human epidermis and on human skin biopsies. These data emphasize the depigmenting effect of metformin and suggest a clinical strategy for using metformin in the topical treatment of hyperpigmentation disorders.

Dates and versions

inserm-02530586 , version 1 (03-04-2020)



Abdelali Lehraiki, Patricia Abbe, Michaël Cerezo, Florian Rouaud, Claire Regazzetti, et al.. Inhibition of Melanogenesis by the Antidiabetic Metformin. Journal of Investigative Dermatology, 2014, 134 (10), pp.2589-2597. ⟨10.1038/jid.2014.202⟩. ⟨inserm-02530586⟩
31 View
0 Download



Gmail Facebook Twitter LinkedIn More